Short stature is present in between one third and two thirds of patients with 22q11DS7 [B]. The cause of this short stature is most likely to be a combination of constitutional delay of growth and a non-specific feature of the Max Appeal! 22q11DS Consensus Document 21 condition. Only about ten percent of adults with 22q11DS syndrome have short stature8 [B]. However, a small proportion of patients have documented growth hormone deficiency7 [C] and it has been suggested that patients with 22q11DS are at an increased risk of pituitary deficiencies, particularly if abnormalities of the palate are present. Occasionally, other pituitary hormone abnormalities have also been described. Weight is sometimes reduced in the early years, particularly if feeding problems are present, but corrects with age and, indeed, some degree of obesity may then supervene9 [B]. Growth and development should always be monitored in children with 22q11DS and, if growth rates are slower than normal (as opposed to the child having short stature but growing at a normal rate), screening for growth hormone deficiency is justified [D]. This can initially be undertaken by measurement of IGF-1 but, if there is any doubt, growth hormone dynamic testing should be undertaken since treatment with growth hormone can then be instituted.

reference - Max Appeal Consensus Document